GSK Acquires Elsie Biotechnologies to Advance Oligonucleotide Platform and Pipeline Therapies
Shots:
- GSK has completed the acquisition of Elsie Biotechnologies for up to $50M to advance its oligonucleotide platform and pipeline medicines
- Following their partnership in Jul 2023 to investigate the technology, this acquisition enables GSK to advance its platform R&D capabilities by combining Elsie’s oligonucleotide discovery, synthesis & delivery technologies
- The information obtained through the Elsie platform will be utilized with GSK’s expertise in AI and ML to develop predictive models for future oligonucleotide design. Additionally, GSK is developing oligonucleotide therapeutics for addressing chronic hepatitis B and steatotic liver disease and other therapeutic areas
Ref: GSK | Image: GSK
Related News:- GSK Highlights P-III (DREAMM-8) Study Data of Blenrep Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma at ASCO 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
